AstraZeneca helped patients save $1.2 billion through its prescription savings programs in 2012.
AstraZeneca announced today that it helped 562,000 patients save $1.2 billion on nearly 4.6 million free prescriptions through its AZ&Me Prescription Savings programs in 2012.
See the table below for details on how many patients in each state received free medicines from AstraZeneca through the programs.
“At AstraZeneca, we believe it is not enough to simply make medicines,” said Jennifer McGovern, Director, Patient Assistance Programs. “We work with patients and caregivers to help make sure that people who need our medicines have access to them – including by providing them free to qualifying patients under our prescription savings programs.”
AstraZeneca’s prescription savings programs include:
- AZ&Me Prescription Savings program for people without insurance: AstraZeneca medicines are provided at no cost to qualifying individuals without prescription drug coverage and who have an annual income at or below $35,000 for an individual or $70,000 for a family of four.
- AZ&Me Prescription Savings program for people with Medicare Part D: AstraZeneca medicines are provided at no cost to qualifying individuals enrolled in Medicare Part D and who have an annual income at or below $35,000 for an individual or $48,000 for a couple.
- AZ&Me Prescription Savings program for healthcare facilities: AstraZeneca medicines are provided in bulk at no cost to qualifying nonprofit organizations, such as disproportionate share hospitals, community health centers, and community free clinics that have an on-site, nonretail, outpatient licensed pharmacy or dispensary. Qualifying individuals without prescription drug coverage, through private insurance or government programs, and who have an annual income at or below $35,000 for an individual or $70,000 for a family of four may obtain their AstraZeneca medicines for free from these facilities.
Here are state by state details (click on the state name to see the full news release for that state):